金斯瑞生物科技(01548.HK)附属治疗多发性骨髓瘤药物 研究更新总缓解率为98%
金斯瑞生物科技(01548.HK)公布,非全资附属传奇生物科技2021年美国临床肿瘤学会(ASCO)年会和欧洲血液学协会(EHA)线上虚拟大会上,公布关於靶向B细胞成熟抗原(BCMA)的嵌合抗原受体T细胞(CAR-T)疗法西达基奥仑赛Ciltacabtagene Autoleucel(cilta-cel)的最新及更新结果,该疗法用於治疗复发和╱或难治性多发性骨髓瘤(RRMM)。
CARTITUDE-1 1b/2期研究的更新结果(其中包括97位经过大量前期治疗的患者)显示,18个月中位随访的总缓解率(ORR)为98%,其中80%的患者达到严格意义的完全缓解(sCR)突显出随着时间推移缓解不断加深(ASH 2020公布资料为67%)。18个月无进展生存(PFS)率为66%(95%置信区间CI,54.9–75.0),总生存率(OS)为81%(95%CI,71.4–87.6)。患者之前接受了中位数六线治疗(范围3–18);其中88%的患者三重耐药,42%的患者五重耐药。对於预先指定的各亚组,缓解率具有可比性(范围90–100%),包括先前治疗线数,髓外浆细胞瘤和细胞遗传学风险方面。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.